title: Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
abstract: Nitric oxide (NO) is synthetized enzymatically from l-arginine (l-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of l-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH(4)) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS depends on substrate and cofactor availability. The importance of BH(4) as a critical regulator of eNOS function suggests that BH(4) may be a rational therapeutic target in vascular disease states. BH(4) oxidation appears to be a major contributor to vascular dysfunction associated with hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases as it leads to the increased formation of oxygen-derived radicals due to NOS uncoupling rather than NO. Accordingly, abnormalities in vascular NO production and transport result in endothelial dysfunction leading to various cardiovascular disorders. However, some disorders including a wide range of functions in the neuronal, immune and cardiovascular system were associated with the over-production of NO. Inhibition of the enzyme should be a useful approach to treat these pathologies. Therefore, it appears that both a lack and excess of NO production in diseases can have various important pathological implications. In this context, NOS modulators (exogenous and endogenous) and their therapeutic effects are discussed.
authors.affiliation: Laboratoire de Physiopathologie et Pharmacologies Cardio-Métaboliques (LPPCM), France. Electronic address: luc.rochette@u-bourgogne.fr.
authors.forename: Luc
authors.initials: L
authors.lastname: Rochette
authors.forename: Julie
authors.initials: J
authors.lastname: Lorin
authors.forename: Marianne
authors.initials: M
authors.lastname: Zeller
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Guilland
authors.forename: Luc
authors.initials: L
authors.lastname: Lorgis
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
authors.forename: Catherine
authors.initials: C
authors.lastname: Vergely
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*
chemical_list: D004791:Enzyme Inhibitors; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase
keywords: 6-pyruvoyl tetrahydropterin synthase; 7,8-dihydroneopterin 30 triphosphate; 8-Oxoguanine DNA glycosylase; ADMA; AF; AGXT2; AP-1; ARE; AT; ApoE-KO; AscH(−); BH(3); BH(4); CAAs; CAT; CATs; CR; CV; CaM; Cardiovascular disease; DDAHs; DHFR; DHPR; DM; DMA; DMGV; DNTP; ERK; FAD; FMN; FOS; FOXO; Finkel–Biskis–Jinkins osteosarcoma; Free radicals; GP; GPx; GSH; GTP; GTP cyclohydrolase 1; GTP-CH; HIF; HSP; JNK; LDL; LTL; MAO; MAPK; MDA; MT; N(G)-monomethyl-l-arginine; N-nitro-l-arginine; N-omega-hydroxy-l-arginine; NADPH; NADPH oxidase; NF-κB; NO; NO inhibitors; NO synthases; NOHA; NOX; NTPH; Nrf2; OGG1; OS; PAH; PCD; PRMT; PTPS; Prx; RNS; ROS; Ref-1; S-adenosyl-l-homocysteine; S-adenosyl-l-methionine; SAH; SAM; SDMA; SOD; SR; TH; TocH; Trx; UA; activator protein 1; alanine-glyoxylate aminotransferase 2; angiotensin; antioxidant response element; apolipoprotein E knockout; ascorbate anion; asymmetric dimethylarginine; atrial fibrillation; c-Jun N-terminal kinase; calmodulin; carbonyl reductase; cardiovascular; catalases; cationic amino acid transporters; cationic amino acids; diabetes mellitus; dihydrofolate reductase; dihydropteridine reductase; dimethylamines; dimethylarginine dimethylaminohydrolases; eGFR; estimated glomerular filtration rate; extracellular signal-regulated kinase; flavin adenine dinucleotide; flavin mononucleotide; forkhead protein; glutathione; glutathione peroxidases; glutathioneperoxidase; guanosine triphosphate; heat shock protein; hypoxia-inducible factor; l-Arg; l-NMMA; l-NNA; l-arginine; leukocyte telomere length; low-density lipoprotein; malondialdehyde; metallothionein; mitogen-activated protein kinase; monoamine oxidase; neuronal tryptophan hydroxylase; nicotinamide dinucleotide phosphate; nitric oxide; nuclear factor erythroid 2-related factor 2; nuclear factor κB; oxidative stress; peroxyredoxin; phenylalanine hydroxylase; protein arginine methyl transferase; pterin-4a-carbinolamine dehydratase; reactive nitrogen species; reactive oxygen species; redox factor-1; sepiapterin reductase; siRNAs; small interfering ribonucleic acids; superoxide dismutase; symmetric dimethylarginine; tHcy; tetrahydrobiopterin; thioredoxin; tocopherol; total plasma homocysteine; trihydrobiopterin radical; tyrosine hydroxylase; uric acid; y+L AA; y+LAT transporters; α-keto-δ-(N(G),N(G)-dimethylguanidino)valeric acid